PARP inhibitors in cancer: moving beyond BRCA
- PMID: 21862406
- DOI: 10.1016/S1470-2045(11)70236-4
PARP inhibitors in cancer: moving beyond BRCA
Comment on
-
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.Lancet Oncol. 2011 Sep;12(9):852-61. doi: 10.1016/S1470-2045(11)70214-5. Epub 2011 Aug 19. Lancet Oncol. 2011. PMID: 21862407 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical